Older, More Diverse Patients Enrolled in COPERNICUS

Luis E. Raez, MD, of Miami Cancer Institute, reviews baseline characteristics from the early safety analysis of COPERNICUS, which tested subcutaneous amivantamab plus lazertinib in epidermal growth factor receptor–mutated lung cancer. Median follow-up was 4.9 months, 89% of participants remained on study, and 3% had received 1 chemotherapy cycle before enrollment. With a median age of 66 years and more patients 65 and older and 75 and older than in MARIPOSA, Wade T. Iams, MD, of Tennessee Oncology, says the data help him answer older patients who ask whether trial participants resemble them. Dr Raez notes that trials often favor younger, fitter patients, so this older population better reflects real life. Dr Iams credits broad enrollment to allowing 1 chemotherapy cycle before molecular results and opening community sites closer to patients. Dr Raez observes that most trials he runs would exclude such patients and argues that trials need to be easier to join.